journal article
Oct 22, 2012
Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling
Topics
No keywords indexed for this article. Browse by subject →
References
67
[1]
Cruickshank JM . Beta-blockers and heart failure. Indian Heart J 2010; 62: 101–10.
[2]
de Groote P, Ennezat PV, Mouquet F . Bisoprolol in the treatment of chronic heart failure. Vasc Health Risk Manag 2007; 3: 431–9.
[3]
McGavin JK, Keating GM . Bisoprolol: a review of its use in chronic heart failure. Drugs 2002; 62: 2677–96.
10.2165/00003495-200262180-00017
[4]
Papadopulos DP, Papademetriou V . Low-dose fixed combination of bisoprolol /hydrochlorothiazide as first line for hypertension: a review of the rationale and clinical evidence. Angiology 2009; 60: 601–7.
10.1177/0003319708324926
[5]
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
The Lancet
10.1016/s0140-6736(98)11181-9
[6]
Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure
Hans L. Hillege, Dorothea Nitsch, Marc A. Pfeffer et al.
Circulation
2006
10.1161/circulationaha.105.580506
[7]
Damman K, Voors AA, Hillege HL, Navis G, Lechat P, van Veldhuisen DJ, et al. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Heart Fail 2010; 12: 974–82.
10.1093/eurjhf/hfq118
[8]
López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004; 25: 1341–62.
10.1016/j.ehj.2004.06.002
[9]
Brophy KM, Scarlett-Ferguson H, Webber KS . Clinical drug therapy for Canadian practice. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2010.
[10]
Kirch W, Rose I, Demers HG, Leopold G, Pabst J, Ohnhaus EE . Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. Clin Pharmacokinet 1987; 13: 110–7.
10.2165/00003088-198713020-00003
[11]
Nestorov I . Whole body pharmacokinetic models. Clin Pharmacokinet 2003; 42: 883–908.
10.2165/00003088-200342100-00002
[12]
Rowland M, Balant L, Peck C . Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29–30, 2002). AAPS PharmSci 2004; 6: E6.
10.1208/ps060106
[13]
Edginton AN, Theil FP, Schmitt W, Willmann S . Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol 2008; 4: 1143–52.
10.1517/17425255.4.9.1143
[14]
Rowland M, Peck C, Tucker G . Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011; 51: 45–73.
10.1146/annurev-pharmtox-010510-100540
[15]
Le Jeunne C, Poirier JM, Cheymol G, Ertzbischoff O, Engel F, Hugues FC . Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers. Eur J Clin Pharmacol 1991; 41: 171–4.
10.1007/bf00265912
[16]
Leopold G, Pabst J, Ungethüm W, Bühring KU . Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist. J Clin Pharmacol 1986; 26: 616–21.
10.1002/j.1552-4604.1986.tb02959.x
[17]
Ding L, Zhou X, Guo X, Song Q, He J, Xu G . LC-ESI-MS method for the determination of bisoprolol in human plasma. J Pharm Biomed Anal 2007; 44: 520–5.
10.1016/j.jpba.2007.03.001
[18]
Jones HM, Gardner IB, Watson KJ . Modelling and PBPK simulation in drug discovery. AAPS J 2009; 11: 155–66.
10.1208/s12248-009-9088-1
[19]
Jones HM, Dickins M, Youdim K, Gosset JR, Attkins NJ, Hay TL, et al. Application of PBPK modelling in drug discovery and development at Pfizer. Xenobiotica 2012; 42: 94–106.
10.3109/00498254.2011.627477
[20]
Simulations Plus, Inc. GastroPlus 7.0 manual. California: The Inc; 2010.
[21]
Jones HM, Parrott N, Jorga K, Lavé T . A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 2006; 45: 511–42.
10.2165/00003088-200645050-00006
[22]
Poirier A, Funk C, Scherrmann JM, Lavé T . Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. Mol Pharm 2009; 6: 1716–33.
10.1021/mp8002495
[23]
Rodgers T, Leahy D, Rowland M . Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 2005; 94: 1259–76.
10.1002/jps.20322
[24]
Rodgers T, Rowland M . Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 2006; 95: 1238–57.
10.1002/jps.20502
[25]
Parrott N, Davies B, Hoffmann G, Koerner A, Lave T, Prinssen E, et al. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants. Clin Pharmacokinet 2011; 50: 613–23.
10.2165/11592640-000000000-00000
[26]
Hinderling PH . Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol Rev 1997; 49: 279–95.
10.1016/s0031-6997(24)01329-2
[27]
Yang J, Jamei M, Yeo KR, Rostami-Hodjegan A, Tucker GT . Misuse of the well-stirred model of hepatic drug clearance. Drug Metab Dispos 2007; 35: 501–2.
10.1124/dmd.106.013359
[28]
Gabrielsson J, Weiner D . Pharmacokinetic and pharmacodynamic data analysis: concept and applications, 4th ed. Stockholm: Swedish Pharmaceutical Press; 2006.
[29]
Lin JH . Species similarities and differences in pharmacokinetics. Drug Metab Dispos 1995; 22: 1008–21.
10.1016/s0090-9556(25)06742-x
[30]
Lin JH . Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos 1998; 26: 1202–12.
[31]
Agoram B, Woltosz WS, Bolger MB . Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001; 50: S41–67.
10.1016/s0169-409x(01)00179-x
[32]
Huang W, Lee SL, Yu LX . Mechanistic approaches to predicting oral drug absorption. AAPS J 2009; 11: 217–24.
10.1208/s12248-009-9098-z
[33]
Li GF, Yang J, Zhang XY, Zhao HR . Physiologically based gastrointestinal models for the prediction of oral drug absorption. Chin J Clin Pharmacol Ther 2010; 15: 656–62. Chinese.
[34]
Kuentz M, Nick S, Parrott N, Röthlisberger D . A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur J Pharm Sci 2006; 27: 91–9.
10.1016/j.ejps.2005.08.011
[35]
Parrott N, Paquereau N, Coassolo P, Lave T . An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. J Pharm Sci 2005; 94: 2327–43.
10.1002/jps.20419
[36]
Reddy MB, Connor A, Brennan BJ, Morcos PN, Zhou A, McLawhon P, et al. Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible. Biopharm Drug Dispos 2011; 32: 261–75.
10.1002/bdd.756
[37]
Davies B, Morris T . Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093–5.
10.1023/a:1018943613122
[38]
Dressman JB, Amidon GL, Reppas C, Shah VP . Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 1998; 15: 11–22.
10.1023/a:1011984216775
[39]
Zhang X, Lionberger RA, Davit BM, Yu LX . Utility of physiologically based absorption modeling in implementing quality by design in drug development. AAPS J 2011; 13: 59–71.
10.1208/s12248-010-9250-9
[40]
National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC). National Health and Nutrition Examination Survey data. Hyattsville, MD: CDC, 2010.
[41]
Ogiu N, Nakamura Y, Ijiri I, Hiraiwa K, Ogiu T . A statistical analysis of the internal organ weights of normal Japanese people. Health Phys 1997; 72: 368–83.
10.1097/00004032-199703000-00004
[42]
Mannhold R, Poda GI, Ostermann C, Tetko IV . Calculation of molecular lipophilicity: State-of-the-art and comparison of log P methods on more than 96 000 compounds. J Pharm Sci 2008; 98: 861–93.
10.1002/jps.21494
[43]
De Buck SS, Sinha VK, Fenu LA, Gilissen RA, Mackie CE, et al. The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab Dispos 2007; 35: 649–59.
10.1124/dmd.106.014027
[44]
Lee AC, Crippen GM . Predicting pKa. J Chem Inf Model 2009; 49: 2013–33.
10.1021/ci900209w
[45]
Rodgers T, Leahy D, Rowland M . Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat. J Pharm Sci 2005; 94: 1237–48.
10.1002/jps.20323
[46]
Gomeni R . PHARM — an interactive graphic program for individual and population pharmacokinetic parameter estimation. Comput Biol Med 1984; 14: 25–34.
10.1016/0010-4825(84)90017-9
[47]
Abuasal BS, Bolger MB, Walker DK, Kaddoumi A . In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate. Mol Pharm 2012; 9: 492–504.
10.1021/mp200275j
[48]
Tubic M, Wagner D, Spahn-Langguth H, Bolger MB, Langguth P . In silico modeling of nonlinear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. Pharm Res 2006; 23: 1712–20.
10.1007/s11095-006-9020-7
[49]
Peters SA . Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles. Clin Pharmacokinet 2008; 47: 245–59.
10.2165/00003088-200847040-00003
[50]
Peters SA, Hultin L . Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat. J Pharmacokinet Pharmacodyn 2008; 35: 1–30.
10.1007/s10928-007-9073-1
Showing 50 of 67 references
Metrics
64
Citations
67
References
Details
- Published
- Oct 22, 2012
- Vol/Issue
- 33(11)
- Pages
- 1359-1371
- License
- View
Authors
Cite This Article
Guo-Fu Li, Kun Wang, Rui Chen, et al. (2012). Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling. Acta Pharmacologica Sinica, 33(11), 1359-1371. https://doi.org/10.1038/aps.2012.103
Related
You May Also Like
Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19
Yuan Huang, Chan Yang · 2020
1,974 citations
Amyloid beta: structure, biology and structure-based therapeutic development
Guo-fang Chen, Ting-Hai Xu · 2017
1,749 citations
Engineering exosomes as refined biological nanoplatforms for drug delivery
Xin Luan, Kanokwan Sansanaphongpricha · 2017
1,056 citations
New knowledge of the mechanisms of sorafenib resistance in liver cancer
Yan-jing Zhu, Bo Zheng · 2017
564 citations
Salvia miltiorrhizaBurge (Danshen): a golden herbal medicine in cardiovascular therapeutics
Zhuo-ming Li, Suo-wen Xu · 2018
474 citations